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CLINICAL/SCIENTIFIC NOTES

OPEN ACCESS
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Signiﬁcance of CD8+ and Natural Killer Cells
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Dimethyl fumarate (DMF), approved for relapsing-remitting multiple sclerosis (RRMS), exerts
immune-mediated mechanisms crucial for T-cell survival and migration, preferentially reducing
CD8+ T cells.1 Although baseline absolute lymphocyte count (ALC) is considered the most
critical predictor of developing lymphopenia,2 it was recently concluded that lymphocyte subset
monitoring is not required for safety vigilance because T-cell subset reduction does not increase
risks for serious infections.3
We present 2 young patients with RRMS, under DMF treatment, negative for HIV and SARSCoV-2 (by RT-PCR in nasal swab) and with normal follow-up white blood cell (WBC)/ALC
counts, who developed severe herpes zoster (HZ) infection with normal ALC but low CD8+
and high CD56bright natural killer (NK) cells, and discuss the potential signiﬁcance of T-cell
immunophenotyping in HZ manifestation.

Patient 1
A 23-year-old woman was seen at age 16 years with acute cerebellar ataxia and trigeminal
neuralgia. MRI showed nonenhancing T2-hyperintense periventricular and subtentorial lesions
and CSF oligoclonal bands. Anti-AQP4 and anti-MOG antibodies were negative. After 6 months,
new T2-hyperintense, enhancing, periventricular lesions developed and was started on interferon
beta-1a with excellent response. Because of new enhancing cervical and thoracic demyelinating
MRI lesions, she was started on DMF 240 mg BID 2 years ago. In March, during the ﬁrst peak of
COVID-19, she presented with an aggressive, blistering rash extending from the right side of back
to the chest (ﬁgure), typical of HZ with positive anti-varicella-zoster virus (VZV) antibodies. She
reported chickenpox in childhood. DMF was discontinued, and 1-week treatment with brivudine
(bromovinyldeoxyuridine) began followed by valaciclovir 1,000 mg TID for 20 days, tapered to
500 mg daily. Her WBC and ALC counts were normal but had low CD3+, very low CD8+, lownormal CD4+ T cells, and very high NK cells (table). After 2 months, the rash improved.
Repeated MRI of the brain and cervical spine was stable. She was started on glatiramer acetate
40 mg 3 times/wk. After 3 months, CD3+, CD4+, and CD8+ T subsets remain still low (table).
Although SARS-CoV-2-PCR was negative and always asymptomatic, she had antibodies to SARSCoV-2-spike protein when tested 10 months after the HZ manifestation.

Patient 2
A 42-year-old man was admitted at age 28 years, with acute right arm numbness and dysuria. He
had 2 other acute episodes 2 years earlier. MRI revealed multiple T2-hyperintense
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Figure Herpes Zoster-Rash

Extensive, blistering, herpes zoster (HZ) rash
extending from the right back to the anterior
chest in (A) patient 1 and from the left back to the
anterior chest in (B) patient 2.

periventricular, subcortical, and cervical lesions. He was given
glatiramer acetate but because of 2 subsequent relapses was
started on DMF 240 mg BID 2 years ago. In October, during
the COVID-19 peak, he developed an aggressive blistering
rash, extending from his left back to the chest, typical of HZ
with positive anti-VZV antibodies (ﬁgure). DMF was discontinued and was treated with 2-week brivudine followed by
valaciclovir 1,000 mg TID for 30 days, tapered to 500 mg
daily. WBC and ALC were slightly below normal (grade-1
lymphocytopenia), but immunophenotyping showed low
CD3, very low CD8+, and very high NK cells with increased
CD4+ and CD19+ T cells (table). After 1 month, the rash
improved, but his CD3+ and CD8-T cells remain low and NK
cells high (table). MRI showed a new enhancing demyelinating cervical lesion, treated with corticosteroids. He
was SARS-CoV-2-antibody-negative.

Discussion
VZV is a lymphotropic virus, which in immunosuppressed patients can be reactivated leading to HZ infection. Our patients
are probably the ﬁrst young, not immunodeﬁcient patients with
normal ALC to manifest severe HZ while on DMF, without any
new CNS-clinical signs to warrant CSF examination. The study
of their T-cell immunophenotyping at onset and after the

infection revealed low CD8+ T cells and increased CD56bright
NK cells that may be implicated in extensive HZ manifestation.
VZV acts on immune cells through cell-surface proteins, like
programmed cell death protein 1 (PD-1), eliciting an immunoinhibitory function and reducing T-cell activation and
cytokine secretion. DMF causes reduction of CD8+ T-cells,
and CD8-cell depletion is associated with increased VZV
reactivation,4,5 but whether in both our patients, the noted
CD8+ T-cell reduction was the only culprit is unclear.
DMF also upregulates CD56bright NK cells, which, in turn,
inhibits CD4+ and CD8+ IFN γ-producing T-cell populations,
promoting an anti-inﬂammatory state and enhancing its
beneﬁcial eﬀects in DMF-treated patients.6 VZV can however
cause a productive infection of human CD56bright NK cells
and upregulates surface expression of chemokine receptors
associated with traﬃcking to the skin where highly infectious
lesions develop.7 The high number of CD56bright NK cells
noted in both our patients at the onset of skin rash might have
facilitated the spread of VZV to the skin, producing such
aggressive lesions unusual for young nonimmunosuppressed
patients, requiring 6 weeks of antiviral therapy before resolution of skin lesions began. It is likely that the low CD8+ cells
triggered HZ reactivation, but the presence of increased NK

Table Lymphocyte Immunophenotyping at the Time of HZ Onset and at Follow-up Periods, 3 Months Later for Patient 1
and 1 Month for Patient 2

Patient 1

Patient 2

WBC

ALC

CD3+

CD3+CD4+

CD3+CD8+

CD19+

NK

Onset of HZ

5,600

1,800

56.0%; 1,000*

41.9%; 734

13.1%; 230*

12.9%; 235

28.7%; 523*

After 3 mo

4,500

1,700

61.1%; 944*

45.6%; 664

13.8%; 201 *

10.4%; 170

26.3%; 428*

Normal range laboratory 1

>4,000

>1,000

69%–81%; >1,500

40%–55%

22%–30%; >342

7%–18%

6%–15%; <350

Onset of HZ

3,160*

929*

41.4%; 385*

75.5%; 290*

18.3%; 70*

22.2%; 206*

33.8%; 314*

After 1 mo

7,460

1,634

46.4%; 758*

73%; 553*

22.6%; 171*

30%; 490*

22.1%; 361*

Normal range laboratory 2

>3,700

>1,000

75%–85%; >1,000

53%–65%

24–41; >250

3%–18%

<18%; <180

Abbreviations: ALC = absolute lymphocyte count; HZ = herpes zoster, >lower limit of normal, <upper limit of normal; WBC = white blood cell.
The low CD3+CD8+ cells and high NK cells are marked with an asterisk, providing the % and the total cell counts. The immunophenotyping was performed in 2
different laboratories (patient 1, laboratory 1; patient 2, laboratory 2), with different normal range; the cell percentage (%) is therefore representative.
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cells facilitated such an extensive manifestation. Our cases
highlight that T-cell subset monitoring may still have a role
during DMF therapy and that the combination of low CD8/
high NK requires attention. Although rare, the cases raise the
question of pharmacovigilance and consideration for VZV
vaccination in certain DMF-receiving patients.
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